233 related articles for article (PubMed ID: 33031343)
21. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
24. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
25. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.
Jiang X; Yang B; Lu J; Zhan Z; Li K; Ren X
Tumour Biol; 2015 Feb; 36(2):861-9. PubMed ID: 25301443
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment.
Wu WS; Wu CH; Lai SL; Chiu CH; Shih JF; Lee YC; Chen YM
Am J Clin Oncol; 2016 Dec; 39(6):556-562. PubMed ID: 24937633
[TBL] [Abstract][Full Text] [Related]
29. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
Zhang A; Liu B; Xu D; Sun Y
Medicine (Baltimore); 2019 Dec; 98(52):e18435. PubMed ID: 31876723
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
31. Pneumothorax in lung cancer following anlotinib treatment: A case report.
Yang L
Medicine (Baltimore); 2022 Jul; 101(29):e29273. PubMed ID: 35866828
[TBL] [Abstract][Full Text] [Related]
32. [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].
Hao H; Zhang M; Zhang G; Zhu H; Bao W
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):60-64. PubMed ID: 31948540
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
35. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
37. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
[TBL] [Abstract][Full Text] [Related]
39. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
Tseng YH; Hung HY; Sung YC; Tseng YC; Lee YC; Whang-Peng J; Chen YM
J Chemother; 2016; 28(1):50-8. PubMed ID: 25976428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]